



CELL & GENE THERAPY (CGT)

Revolutionizing Personalized Cancer Treatment

CGT would be pivotal in personalized cancer treatments – 5,380 Clinical trials are expected in 2030
 CAR-Ts, TILs, TCR-T cells, γδ-T cells, NK cells, and macrophages cell therapy types are being researched.




Increasing #CGT trials and participation >700 players would disrupt the cancer treatment




*8x and 23x represent increased number of clinical trials when compared to 2015
 *E: Expected

CGT Approval Timeline




Top 5 Cancer Indications by Cell Therapy Types



Top Indications
 Pan-solid tumors, NHL, multiple myeloma

Top Cell Types
 CAR-T, TCR in cell therapy



CD19 & BCMA are the leading targets



Dual/multi targeted cell therapies are being investigated to

- Improve specificity
- Overcome CAR-T resistance

APAC & NA regions account for 90% of CT trials; China is the leading country



*% indicates the distribution of trials for respective cell therapy types and the penetration of the industry and academia in clinical trials

Cell Type

To talk to our experts and a demo of the Cell and Gene Therapy Intelligence Platform, please [connect with us here](#)

About FutureBridge

FutureBridge tracks and advises on the future of industries from a 1-to-25 year perspective. We keep you ahead on the technology curve, propel your growth, identify new opportunities, markets and business models, answer your unknowns, and facilitate best-fit solutions and partnerships using our platforms, programs, and access to global ecosystems and players.